EC
SLRN

EcoR1 Capital’s ACELYRIN SLRN Stock Holding History

EcoR1 Capital’s Portfolio SLRN Stock Details SLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,402,201
Closed -$14.3M – 58
2023
Q3 		$14.3M Buy
+1,402,201
New +$29.8M 0.48% 31

Other funds holding SLRN

ACMC
AyurMaya Capital Management Company Portsmouth, New Hampshire $426M AUM 838% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital's SLRN Position: Q4 2023 in Review

EcoR1 Capital sold out of ACELYRIN (SLRN) in Q4 2023, closing a stake of 1,402,201 shares — an estimated $14.3M sold.

EcoR1 Capital first reported a position in SLRN in Q3 2023 and held it in 1 quarter. The position peaked at $14.3M in Q3 2023. 110 funds tracked by Wall St. Rank hold SLRN as of Q4 2023.

  • EcoR1 Capital reported no remaining ACELYRIN position as of Q4 2023 after selling out during the quarter.
  • EcoR1 Capital sold 1,402,201 ACELYRIN shares in Q4 2023, an estimated $14.3M.
  • EcoR1 Capital first reported a position in ACELYRIN in Q3 2023 and held it in 1 quarter.
  • EcoR1 Capital's ACELYRIN position peaked at $14.3M in Q3 2023.
  • 110 funds tracked by Wall St. Rank held ACELYRIN as of Q4 2023.

Based on EcoR1 Capital's 13F filing for Q4 2023, filed 14 Feb 2024.